Lantern Pharma initiated with a Buy at Lake Street

Lake Street initiated coverage of Lantern Pharma (LTRN) with a Buy rating and $25 price target Lantern’s Response Algorithm for Drug Positioning and Rescue, or RADR, platform consists of a suite of AI modules designed to help advance cancer drug development, the analyst tells investors. Unlike many biotech AI platform companies, Lantern is monetizing RADR through advancement of its own pipeline of four clinical, plus additional preclinical, stage molecules, though they also engage in collaborations with partners, adds the analyst, who notes that lead clinical program LP-300 targets a unique set of lung cancer patients who never smoked.